Clinical Trial: A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu(R)) Pregnant Women (AnFLU-PREG)

U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07832201) titled 'A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu(R)) Pregnant Women (AnFLU-PREG)' on Aug. 28.

Brief Summary: A phase IV clinical trial of Influenza Vaccine (Split Virion), Inactivated (Anflu(R)) developed by Sinovac Biotech Co., Ltd will be conducted in pregnant women.

A total of 150 healthy pregnant women aged 18~45 years at 22 to 34 weeks (+6 days) of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac Influenza Vaccine (Split Virion) , Inactivated (Anflu(R)) or Sanofi VAXIGRIP(R), ...